A 12-month observational study on the safety, efficacy on migraine-associated symptoms and satisfaction of CGRP monoclonal antibodies in Japanese patients with migraine
Shungo Imai(Keio University), Tsubasa Takizawa(Keio University), Jin Nakahara(Keio University Hospital), Satoko Hori(Keio University), Keiko Ihara(Keio University), Chisato Iba(Keio University Hospital), Narumi Watanabe(Keio University Hospital), Ryo Takemura(Keio University Hospital), Seiya Ohtani(Keio University), Nobuyuki Takahashi(Keio University Hospital), Kei Ishizuchi(Keio University Hospital)
Cited by 7
Related Papers
Hallmarks of primary headache: part 1 – migraine
|The Journal of Headache and Pain|2024|174
Spreading depolarizations trigger caveolin‐1–dependent endothelial transcytosis
|Annals of Neurology|2018|107
International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine
|Cephalalgia|2024|107
International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
|Cephalalgia|2024|106
Spreading depression as a preclinical model of migraine
|The Journal of Headache and Pain|2019|104